Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,849 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,388 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03122470 | Correlation of Imaging Findings With Clinical Findings and Patient Outcomes in Prostate Cancer | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Mar 16, 2023 | clinicaltrials |
| NCT04276597 | Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.(PUTNET) | withdrawn | Phase 2 | 0 | Excel Diagnostics and Nuclear Oncology CenterOTHER |
| 1 |
| Mar 10, 2023 |
| clinicaltrials |
| NCT04797078 | US/MRI Fusion Local Anestesia TransPerineal Prostate Biopsies for Detection of Prostate Cancer(FLAPP) | withdrawn | N/A | 0 | Karolinska InstitutetOTHER | 0 | Mar 10, 2023 | clinicaltrials |
| NCT05259397 | PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | withdrawn | Phase 1 | 0 | PfizerINDUSTRY | 2 | Mar 8, 2023 | clinicaltrials |
| NCT01792882 | Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples(GBCPRT0008) | withdrawn | — | 0 | Global BioClinicalINDUSTRY | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05405192 | Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia | withdrawn | Phase 2 | 0 | University of MiamiOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05419817 | Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System | withdrawn | Phase 2 | 0 | Haider MahdiOTHER | 0 | Feb 27, 2023 | clinicaltrials |
| NCT05705700 | Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP) | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Feb 27, 2023 | clinicaltrials |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors(MATILDA) | withdrawn | Phase 2 | 0 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT04941365 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(SERPENTINE) | withdrawn | N/A | 0 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 0 | Dec 22, 2022 | clinicaltrials |
| NCT03987568 | Characterize Tumor Hypoxia by Magnetic Resonance Imaging | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Dec 21, 2022 | clinicaltrials |
| NCT05393635 | ITIL-168 in Advanced Solid Tumors(DELTA-2) | withdrawn | Phase 1 | 0 | Instil BioINDUSTRY | 0 | Dec 20, 2022 | clinicaltrials |
| NCT05062174 | Breast Cancer BRCA1 Carriers: a Pilot Study | withdrawn | — | 0 | Indiana UniversityOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT04742972 | Prostate PMSABR Study | withdrawn | N/A | 0 | Darren PoonOTHER | 0 | Dec 9, 2022 | clinicaltrials |
| NCT04294836 | Curcumin in Advanced Cervical Cancer | withdrawn | Phase 2 | 0 | Instituto Nacional de Cancerologia, ColumbiaOTHER_GOV | 0 | Dec 7, 2022 | clinicaltrials |
| NCT00581503 | Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer | withdrawn | — | 0 | University of California, IrvineOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT04368130 | SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care(SIGNAL) | withdrawn | N/A | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT03709550 | Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT04943627 | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) | withdrawn | Phase 3 | 0 | Agenus Inc.INDUSTRY | 2 | Oct 5, 2022 | clinicaltrials |
| NCT04127318 | Low-moderate Intensity Pedaling During Immunotherapy Administration | withdrawn | N/A | 0 | Rush University Medical CenterOTHER | 1 | Sep 23, 2022 | clinicaltrials |
| NCT02290366 | Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer | withdrawn | N/A | 0 | Ronald M. Benoit, MDOTHER | 1 | Aug 29, 2022 | clinicaltrials |
| NCT05395260 | FL- 101 Study in Non-Metastatic MIBC | withdrawn | Early Phase 1 | 0 | Flame BiosciencesINDUSTRY | 0 | Aug 19, 2022 | clinicaltrials |
| NCT01769885 | Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer | withdrawn | N/A | 0 | Roswell Park Cancer InstituteOTHER | 0 | Aug 15, 2022 | clinicaltrials |
| NCT04972253 | Phase I BLASST-3 Trial((BLASST)-3) | withdrawn | Phase 1 | 0 | Guru P. SonpavdeOTHER | 0 | Aug 10, 2022 | clinicaltrials |
| NCT05191017 | Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | withdrawn | Phase 1 / Phase 2 | 0 | Nuvation Bio Inc.INDUSTRY | 1 | Aug 5, 2022 | clinicaltrials |
| NCT05263609 | Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib | withdrawn | Phase 2 | 0 | University of OklahomaOTHER | 0 | Aug 2, 2022 | clinicaltrials |
| NCT02117817 | Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer | withdrawn | Phase 1 | 0 | Rutgers, The State University of New JerseyOTHER | 0 | Jul 28, 2022 | clinicaltrials |
| NCT04288336 | Daily, Long-Term Intermittent Fasting for the Prevention of PSA-Recurrence in Patients With Localized Prostate Cancer After Radical Prostatectomy | withdrawn | Early Phase 1 | 0 | Mayo ClinicOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT04941378 | OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer | withdrawn | Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 27, 2022 | clinicaltrials |
| NCT03834571 | Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women | withdrawn | Phase 2 | 0 | AIDS Malignancy ConsortiumNETWORK | 2 | Jun 21, 2022 | clinicaltrials |
| NCT04961320 | Occupational Therapy Fatigue Management-Based Intervention for Metastatic Renal Cell Carcinoma | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 0 | Jun 9, 2022 | clinicaltrials |
| NCT03823001 | Virtual Prostate Biopsy Protocol for Patients on Active Surveillance and at Risk of Prostate Cancer | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | May 20, 2022 | clinicaltrials |
| NCT03839472 | Continuous Bladder Irrigation Following Transurethral Resection of Bladder Tumors | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT05104905 | A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma(RENACOL) | withdrawn | Phase 1 / Phase 2 | 0 | Faron Pharmaceuticals LtdINDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT04806945 | A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer | withdrawn | Phase 3 | 0 | Shanghai Henlius BiotechINDUSTRY | 1 | May 5, 2022 | clinicaltrials |
| NCT04630483 | Platelet-lymphocyte and Neutrophil-lymphocyte Ratio in Patients Undergoing Cancer Surgery | withdrawn | — | 0 | Medipol UniversityOTHER | 1 | May 4, 2022 | clinicaltrials |
| NCT04331717 | Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer(BASH-PC) | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT04795596 | Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers | withdrawn | Phase 2 / Phase 3 | 0 | Menoufia UniversityOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT05260788 | Mapping 3D Bladder | withdrawn | — | 0 | University Health Network, TorontoOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Silverback TherapeuticsINDUSTRY | 0 | Apr 12, 2022 | clinicaltrials |
| NCT02061605 | First-in-Human Safety Study Of Laser Tissue Welding For Surtureless Laparoscopic Partial Nephrectomy(LTW-KIDNEY) | withdrawn | N/A | 0 | Laser Tissue Welding, Inc.INDUSTRY | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03977311 | MR-Guided High-Intensity Focused Ultrasound in Conjunction With Radiation Therapy for the Treatment of Locally Advanced Cervical Cancer | withdrawn | N/A | 0 | Washington University School of MedicineOTHER | 0 | Apr 1, 2022 | clinicaltrials |
| NCT04765423 | Fluciclovine (Axumin) PET/CT vs. NaF PET/CT in Prostate Cancer Osseous Metastatic Disease | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT00482157 | Calcitriol or Placebo in Men for Prostate Cancer Active Surveillance | withdrawn | N/A | 0 | Stanford UniversityOTHER | 0 | Mar 3, 2022 | clinicaltrials |
| NCT04611139 | Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers | withdrawn | Phase 1 | 0 | HonorHealth Research InstituteOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT01826838 | Study of Dasatinib, Androgen Deprivation Therapy and Radiation(BrUOGPR255) | withdrawn | Phase 1 | 0 | Brown UniversityOTHER | 0 | Feb 24, 2022 | clinicaltrials |
| NCT03035630 | Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | Guru SonpavdeOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT04339920 | Spermine Measuring Device Evaluation Protocol | withdrawn | — | 0 | Chinese University of Hong KongOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT03905902 | DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma(VITALIA) | withdrawn | Phase 3 | 0 | SOTIO a.s.INDUSTRY | 0 | Dec 23, 2021 | clinicaltrials |
| NCT03800784 | Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 15, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Mar 16, 2023source: clinicaltrials